Enclony partners with Johnson & Johnson on drug sample inspection project

Enclony, a Korean company specializing in automated pharmaceutical inspection and printing equipment, said Thursday that it is collaborating with global pharmaceutical giant Johnson & Johnson on a new drug sample inspection project.

As part of the initiative, Enclony is overseeing the visual inspection of refined drug samples, including capsules, pressed tablets, and compacted tablets, for defects at Johnson & Johnson’s facilities in Italy, Belgium, and Japan. Specific details about the tablets or reagents involved were not disclosed.

The project is being managed by Johnson & Johnson’s Fuji site in Japan, which oversees pharmaceutical quality control.

“We’ve observed an increasing variety and quantity of new drug samples compared to the project’s initial stages,” said an Enclony official. “Our equipment’s technological excellence has been highly recognized during this collaboration, positioning us favorably for potential inspection equipment supply contracts when Johnson & Johnson establishes new manufacturing lines and facilities.”

Enclony and Johnson & Johnson began their partnership in 2018 when Enclony was selected as a pharmaceutical inspection equipment supplier through a global bidding process.

Since then, the Enclony official said the two companies have maintained a strong relationship. In addition to the current sample inspection project, Enclony signed a contract in May to supply a second piece of equipment to Johnson & Johnson’s manufacturing facility in China.

“From the beginning, we have focused on leveraging our technology to target global pharmaceutical companies,” said Enclony CEO Lee Gyeong-ho. He added, “This project highlights the strength of our technology and sets the stage for long-term partnerships."